• 主题
高级搜索  >
历史搜索 清空历史
首页> 美国卫生研究院文献>British Journal of Cancer >British National Lymphoma Investigation randomised study of MOPP (mustine Oncovin procarbazine prednisolone) against LOPP (Leukeran substituted for mustine) in advanced Hodgkins disease--long term results.
【2h】

British National Lymphoma Investigation randomised study of MOPP (mustine Oncovin procarbazine prednisolone) against LOPP (Leukeran substituted for mustine) in advanced Hodgkins disease--long term results.

机译：英国国家淋巴瘤调查针对晚期霍奇金病的MOPP（麝香Oncovin丙卡巴肼泼尼松龙）对抗LOPP（用Leukeran替代芥子碱）的随机研究-长期结果。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

From 1979-1983, 299 patients with stage III or IV Hodgkin's disease (HD) were randomised to receive cyclical chemotherapy with MOPP (mustine, Oncovin, procarbazine, prednisone) or LOPP (Leukeran substituted for mustine). Two hundred and ninety patients were evaluable. There was no statistically significant difference between the complete remission (CR) rates (63% for MOPP, 57% for LOPP), percentage of patients remaining disease free at 5 years (38% for MOPP, 35% for LOPP) and overall survival at 5 years (65% for MOPP, 64% for LOPP). On multivariate analysis younger age, grade I histopathology, absence of systemic symptoms, and normal albumin level were favourable prognostic factors for survival. Acute toxicity in the form of nausea/vomiting, myelosuppression, and phlebitis were less with LOPP than MOPP. Deaths in both groups were usually due to disseminated Hodgkin's disease; there were no infective deaths in the absence of Hodgkin's disease. Second malignancies occurred in six patients treated with MOPP--three acute myeloid leukaemia (AML), one non-Hodgkin's lymphoma (NHL), two carcinomas (Ca); with LOPP, four second malignancies occurred (one AML, one NHL, two Ca). These long term results confirm that LOPP is as effective as MOPP, and less toxic, in the treatment of advanced Hodgkin's disease.
机译：从1979年至1983年，将299例III期或IV期霍奇金病（HD）患者随机分配接受MOPP（麝香，Oncovin，Procarbazine，泼尼松）或LOPP（用Leukeran替代芥末）的周期性化疗。 290名患者是可评估的。完全缓解（CR）率（MOPP为63％，LOPP为57％），5年无疾病的患者百分比（MOPP为38％，LOPP为35％）与总生存期之间无统计学差异。 5年（MOPP为65％，LOPP为64％）。在多因素分析中，较年轻的年龄，I级组织病理学，无全身症状和白蛋白水平正常是生存的有利预后因素。 LOPP的恶心/呕吐，骨髓抑制和静脉炎等急性毒性低于MOPP。两组的死亡通常是由于传播的霍奇金病引起的。在没有霍奇金病的情况下，没有感染性死亡。第二例恶性肿瘤发生在6例接受MOPP治疗的患者中-3例急性髓细胞性白血病（AML），1例非霍奇金淋巴瘤（NHL），2例癌（Ca）。使用LOPP时，发生四次第二次恶性肿瘤（一个AML，一个NHL，两个Ca）。这些长期结果证实，LOPP在治疗晚期霍奇金病方面与MOPP一样有效，并且毒性较低。

著录项

相似文献

  • 外文文献
代理获取

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号